Research ExplorerPublicationsImpact on follow-up strategies in patients with primary scle...

Impact on follow-up strategies in patients with primary sclerosing cholangitis

Standard

Impact on follow-up strategies in patients with primary sclerosing cholangitis. / Bergquist, Annika; Weismüller, Tobias J; Levy, Cynthia; Rupp, Christian; Joshi, Deepak; Nayagam, Jeremy Shanika; Montano-Loza, Aldo J; Lytvyak, Ellina; Wunsch, Ewa; Milkiewicz, Piotr; Zenouzi, Roman; Schramm, Christoph; Cazzagon, Nora; Floreani, Annarosa; Liby, Ingalill Friis; Wiestler, Miriam; Wedemeyer, Heiner; Zhou, Taotao; Strassburg, Christian P; Rigopoulou, Eirini; Dalekos, George; Narasimman, Manasa; Verhelst, Xavier; Degroote, Helena; Vesterhus, Mette; Kremer, Andreas E; Bündgens, Bennet; Rorsman, Fredrik; Nilsson, Emma; Jørgensen, Kristin Kaasen; von Seth, Erik; Cornillet Jeannin, Martin; Nyhlin, Nils; Martin, Harry; Kechagias, Stergios; Wiencke, Kristine; Werner, Mårten; Beretta-Piccoli, Benedetta Terziroli; Marzioni, Marco; Isoniemi, Helena; Arola, Johanna; Wefer, Agnes; Söderling, Jonas; Färkkilä, Martti; Lenzen, Henrike; International PSC Study Group (IPSCSG).

In: LIVER INT, Vol. 43, No. 1, 01.2023, p. 127-138.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bergquist, A, Weismüller, TJ, Levy, C, Rupp, C, Joshi, D, Nayagam, JS, Montano-Loza, AJ, Lytvyak, E, Wunsch, E, Milkiewicz, P, Zenouzi, R, Schramm, C, Cazzagon, N, Floreani, A, Liby, IF, Wiestler, M, Wedemeyer, H, Zhou, T, Strassburg, CP, Rigopoulou, E, Dalekos, G, Narasimman, M, Verhelst, X, Degroote, H, Vesterhus, M, Kremer, AE, Bündgens, B, Rorsman, F, Nilsson, E, Jørgensen, KK, von Seth, E, Cornillet Jeannin, M, Nyhlin, N, Martin, H, Kechagias, S, Wiencke, K, Werner, M, Beretta-Piccoli, BT, Marzioni, M, Isoniemi, H, Arola, J, Wefer, A, Söderling, J, Färkkilä, M, Lenzen, H & International PSC Study Group (IPSCSG) 2023, 'Impact on follow-up strategies in patients with primary sclerosing cholangitis', LIVER INT, vol. 43, no. 1, pp. 127-138. https://doi.org/10.1111/liv.15286

APA

Bergquist, A., Weismüller, T. J., Levy, C., Rupp, C., Joshi, D., Nayagam, J. S., Montano-Loza, A. J., Lytvyak, E., Wunsch, E., Milkiewicz, P., Zenouzi, R., Schramm, C., Cazzagon, N., Floreani, A., Liby, I. F., Wiestler, M., Wedemeyer, H., Zhou, T., Strassburg, C. P., ... International PSC Study Group (IPSCSG) (2023). Impact on follow-up strategies in patients with primary sclerosing cholangitis. LIVER INT, 43(1), 127-138. https://doi.org/10.1111/liv.15286

Vancouver

Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS et al. Impact on follow-up strategies in patients with primary sclerosing cholangitis. LIVER INT. 2023 Jan;43(1):127-138. https://doi.org/10.1111/liv.15286

Bibtex

@article{d344e45fc3ba413fa012bcae8761db89,
title = "Impact on follow-up strategies in patients with primary sclerosing cholangitis",
abstract = "BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.RESULTS: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.CONCLUSIONS: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.",
author = "Annika Bergquist and Weism{\"u}ller, {Tobias J} and Cynthia Levy and Christian Rupp and Deepak Joshi and Nayagam, {Jeremy Shanika} and Montano-Loza, {Aldo J} and Ellina Lytvyak and Ewa Wunsch and Piotr Milkiewicz and Roman Zenouzi and Christoph Schramm and Nora Cazzagon and Annarosa Floreani and Liby, {Ingalill Friis} and Miriam Wiestler and Heiner Wedemeyer and Taotao Zhou and Strassburg, {Christian P} and Eirini Rigopoulou and George Dalekos and Manasa Narasimman and Xavier Verhelst and Helena Degroote and Mette Vesterhus and Kremer, {Andreas E} and Bennet B{\"u}ndgens and Fredrik Rorsman and Emma Nilsson and J{\o}rgensen, {Kristin Kaasen} and {von Seth}, Erik and {Cornillet Jeannin}, Martin and Nils Nyhlin and Harry Martin and Stergios Kechagias and Kristine Wiencke and M{\aa}rten Werner and Beretta-Piccoli, {Benedetta Terziroli} and Marco Marzioni and Helena Isoniemi and Johanna Arola and Agnes Wefer and Jonas S{\"o}derling and Martti F{\"a}rkkil{\"a} and Henrike Lenzen and {International PSC Study Group (IPSCSG)}",
note = "{\textcopyright} 2022 The Authors. Liver International published by John Wiley & Sons Ltd.",
year = "2023",
month = jan,
doi = "10.1111/liv.15286",
language = "English",
volume = "43",
pages = "127--138",
journal = "LIVER INT",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Impact on follow-up strategies in patients with primary sclerosing cholangitis

AU - Bergquist, Annika

AU - Weismüller, Tobias J

AU - Levy, Cynthia

AU - Rupp, Christian

AU - Joshi, Deepak

AU - Nayagam, Jeremy Shanika

AU - Montano-Loza, Aldo J

AU - Lytvyak, Ellina

AU - Wunsch, Ewa

AU - Milkiewicz, Piotr

AU - Zenouzi, Roman

AU - Schramm, Christoph

AU - Cazzagon, Nora

AU - Floreani, Annarosa

AU - Liby, Ingalill Friis

AU - Wiestler, Miriam

AU - Wedemeyer, Heiner

AU - Zhou, Taotao

AU - Strassburg, Christian P

AU - Rigopoulou, Eirini

AU - Dalekos, George

AU - Narasimman, Manasa

AU - Verhelst, Xavier

AU - Degroote, Helena

AU - Vesterhus, Mette

AU - Kremer, Andreas E

AU - Bündgens, Bennet

AU - Rorsman, Fredrik

AU - Nilsson, Emma

AU - Jørgensen, Kristin Kaasen

AU - von Seth, Erik

AU - Cornillet Jeannin, Martin

AU - Nyhlin, Nils

AU - Martin, Harry

AU - Kechagias, Stergios

AU - Wiencke, Kristine

AU - Werner, Mårten

AU - Beretta-Piccoli, Benedetta Terziroli

AU - Marzioni, Marco

AU - Isoniemi, Helena

AU - Arola, Johanna

AU - Wefer, Agnes

AU - Söderling, Jonas

AU - Färkkilä, Martti

AU - Lenzen, Henrike

AU - International PSC Study Group (IPSCSG)

N1 - © 2022 The Authors. Liver International published by John Wiley & Sons Ltd.

PY - 2023/1

Y1 - 2023/1

N2 - BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.RESULTS: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.CONCLUSIONS: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.

AB - BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.RESULTS: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.CONCLUSIONS: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.

U2 - 10.1111/liv.15286

DO - 10.1111/liv.15286

M3 - SCORING: Journal article

C2 - 35535655

VL - 43

SP - 127

EP - 138

JO - LIVER INT

JF - LIVER INT

SN - 1478-3223

IS - 1

ER -